The purpose of the core is to provide expertise in the use of SCID-hu mice and PCR to other basic and clinical researchers. The SCID-hu and PCR cores are administratively combined for historical reasons. The P1 and the core facility technician have significant expertise in the construction of SCID-hu mice and the detection of HIV DNA and RNA in cells and tissues by PCR. The core will provide researchers with SCID-hu mice to be used as an in vivo model of HIV infection and BNX-hu and nude- hu mice to be used in an in vivo model to test HIV vaccines. The construction of SCID-hu mice and BNC-hu mice is a complicated process that requires a breeding colony of SCID and BNX mice, a source of fetal tissue and the surgical expertise required to construct the mice. In addition, following HIV-1 infection of the SCID-hu or BNX-hu mice, they must be contained in a BSL-3 containment facility. These resources are outside the reach of individual researchers and therefore are best provided as a core facility. The core will also perform diagnosis and quantification of HIV-1 infection by the detection of DNA and RNA PCR which should prove extremely helpful for both clinical and basic researchers. In addition, the core will provide expertise in the assessment of cytokine gene expression which will permit researchers to evaluate the in vivo an in vitro immune response to HIV-1 infection. The presence of a centralized core facility permits these assays to be performed by researchers having a high degree of expertise in this area and in a facility designed to minimize contamination. This results in the high quality control required for reproducible results.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027741-08
Application #
5205347
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
1996
Total Cost
Indirect Cost
Rubinstein, Arye (2005) Preclinical studies of alkylureas as anti-HIV-1 contraceptive. Curr Pharm Des 11:3769-78
Lenz, J; Su, M; Mizrachi, Y et al. (2001) V3 variation in HIV-seropositive patients receiving a V3- targeted vaccine. AIDS 15:577-81
Browning Paul, J; Wang, E J; Pettoello-Mantovani, M et al. (2000) Mice transgenic for monocyte-tropic HIV type 1 produce infectious virus and display plasma viremia: a new in vivo system for studying the postintegration phase of HIV replication. AIDS Res Hum Retroviruses 16:481-92
Rubinstein, A; Mizrachi, Y; Bernstein, L et al. (2000) Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients. AIDS 14:F55-62
Yurasov, S V; Pettoello-Mantovani, M; Raker, C A et al. (1999) HIV type 1 infection of human fetal bone marrow cells induces apoptotic changes in hematopoietic precursor cells and suppresses their in vitro differentiation and capacity to engraft SCID mice. AIDS Res Hum Retroviruses 15:1639-52
Rubinstein, A; Mizrachi, Y; Pettoello-Mantovani, M et al. (1999) Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates. J Acquir Immune Defic Syndr 22:467-76
Pettoello-Mantovani, M; Kollmann, T R; Katopodis, N F et al. (1998) thy/liv-SCID-hu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues. J Infect Dis 177:337-46
Landor, M; Rubinstein, A; Kim, A et al. (1998) Receptor-mediated maternofetal transfer of immunoglobulins. Inhibition of transport of anti-HIV-1 immunoglobulin by generic immunoglobulins in the in vitro perfused placenta. Int Arch Allergy Immunol 115:203-9
Browning, J; Horner, J W; Pettoello-Mantovani, M et al. (1997) Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci U S A 94:14637-41
Harish, Z; Rubinstein, A; Golodner, M et al. (1997) Suppression of HIV-1 replication by propolis and its immunoregulatory effect. Drugs Exp Clin Res 23:89-96

Showing the most recent 10 out of 36 publications